Dec 8, 2025
Annual Report 2025: Expanding Our Innovative Approach
As we close on a successful year and look ahead to 2026, UPMC Enterprises is proud to share our 2025 Annual Report.
As the innovation, commercialization, and venture capital division of the UPMC system, we are uniquely situated at the center of an ongoing transformation at UPMC, which is focused on providing greater access, more convenience, and new innovative medicine to our patients.
At UPMC Enterprises, we are expanding our traditional role of vetting software, supporting digital platforms, and translating cutting-edge science into new treatments by taking on additional strategic initiatives that support the UPMC system.
Read on for a summary of the achievements from UPMC Enterprises, our portfolio companies, and these new initiatives that are furthering the mission and vision of UPMC. And download the full report for all the details.
New Initiatives
UPMC Enterprises remains focused on supporting innovative companies in the digital health and life sciences sectors with capital, connections, and resources. These efforts also have diversified into new areas, including the development of Ahavi, real-world data platform, improving sponsored clinical trials at UPMC, collaborating with UPMC’s expert clinicians and researchers, and supporting the growth of UPMC’s Community and Ambulatory Services division through our UPMC GoHealth Urgent Care partnership.
A Growing Portfolio
Nine companies joined our diverse portfolio in 2025 — Carta Healthcare, Glimmer Health, Koda Health, Latigo Biotherapeutics, Optain Health, Ouro Medicines, Penguin Ai, Percipio Health, and Spark Pediatrics. From digital health companies leveraging AI to biotechnology innovators pursuing new treatments, a core tenet of our investment strategy is to support leading-edge and disruptive companies that are driving innovation that will ultimately benefit patients at UPMC and beyond.
Exits from the Portfolio
We celebrated the next stage in the journey of four of our portfolio companies this year — Edifecs, Kyruus, Q-Centrix, and Xealth.
Milestones of Portfolio Company Progress
The Annual Report spotlights several portfolio companies’ successful achievements including funding rounds, accomplishments in clinical trials, and steps forward in pilot projects and implementations at UPMC. Key highlights include Ultromics’ $55 million series C round, Ouro Medicines’ three milestones for their T cell antibody treatment, SparingVision’s progress in clinical trials of gene therapy treatments, and much more.
Next Steps:
- Download the full report by completing the form below for more on these accomplishments as well as our thought leadership, research reports, and key events.
- Learn more about our focus and approach at UPMC Enterprises.
